Compare EVO & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | MMI |
|---|---|---|
| Founded | 1993 | 1971 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | EVO | MMI |
|---|---|---|
| Price | $3.00 | $28.75 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $28.00 |
| AVG Volume (30 Days) | 107.1K | ★ 153.2K |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | N/A | ★ 84.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $719,700,000.00 |
| Revenue This Year | $1.37 | $14.04 |
| Revenue Next Year | $10.05 | $11.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $24.43 |
| 52 Week High | $4.80 | $33.62 |
| Indicator | EVO | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 71.53 |
| Support Level | $2.87 | $28.27 |
| Resistance Level | $3.78 | $31.56 |
| Average True Range (ATR) | 0.10 | 0.55 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 50.00 | 98.23 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.